Walleye Capital LLC lifted its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) by 111.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,474 shares of the biotechnology company’s stock after purchasing an additional 54,569 shares during the period. Walleye Capital LLC’s holdings in Heron Therapeutics were worth $592,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of HRTX. Envestnet Asset Management Inc. purchased a new stake in Heron Therapeutics in the 4th quarter worth approximately $108,000. Bank of America Corp DE lifted its stake in Heron Therapeutics by 224.1% in the fourth quarter. Bank of America Corp DE now owns 345,244 shares of the biotechnology company’s stock worth $3,152,000 after acquiring an additional 238,708 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Heron Therapeutics by 6.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 336,881 shares of the biotechnology company’s stock valued at $3,076,000 after acquiring an additional 19,682 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Heron Therapeutics by 811.5% during the 4th quarter. BNP Paribas Arbitrage SA now owns 152,981 shares of the biotechnology company’s stock valued at $1,397,000 after purchasing an additional 136,197 shares during the period. Finally, Teacher Retirement System of Texas raised its holdings in Heron Therapeutics by 31.9% in the 4th quarter. Teacher Retirement System of Texas now owns 18,443 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 4,460 shares in the last quarter.
Heron Therapeutics Stock Down 7.3 %
NASDAQ:HRTX opened at $4.33 on Thursday. The company has a debt-to-equity ratio of 6.22, a current ratio of 1.77 and a quick ratio of 1.21. The firm’s 50-day moving average price is $4.02 and its 200-day moving average price is $4.14. The company has a market capitalization of $444.40 million, a PE ratio of -1.94 and a beta of 1.15. Heron Therapeutics, Inc. has a 1-year low of $2.19 and a 1-year high of $12.89.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC cut their target price on shares of Heron Therapeutics from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, June 30th. Cowen cut their price objective on Heron Therapeutics to $5.50 in a research report on Monday, August 15th. Finally, StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
- Get a free copy of the StockNews.com research report on Heron Therapeutics (HRTX)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.